182 related articles for article (PubMed ID: 29735544)
21. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
[TBL] [Abstract][Full Text] [Related]
22. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.
Zhao Q; Qian Q; Cao D; Yang J; Gui T; Shen K
J Ovarian Res; 2018 Apr; 11(1):31. PubMed ID: 29685168
[TBL] [Abstract][Full Text] [Related]
23. Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1.
Nakae A; Kodama M; Okamoto T; Tokunaga M; Shimura H; Hashimoto K; Sawada K; Kodama T; Copeland NG; Jenkins NA; Kimura T
Biochem Biophys Res Commun; 2021 May; 552():120-127. PubMed ID: 33744759
[TBL] [Abstract][Full Text] [Related]
24. Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling.
Ye J; Chen W; Wu ZY; Zhang JH; Fei H; Zhang LW; Wang YH; Chen YP; Yang XM
Oncol Rep; 2016 Dec; 36(6):3588-3596. PubMed ID: 27779718
[TBL] [Abstract][Full Text] [Related]
25. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
26. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Gao Y; Foster R; Yang X; Feng Y; Shen JK; Mankin HJ; Hornicek FJ; Amiji MM; Duan Z
Oncotarget; 2015 Apr; 6(11):9313-26. PubMed ID: 25823654
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
28. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL
Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
[TBL] [Abstract][Full Text] [Related]
30. Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.
Lyu T; Jia N; Wang J; Yan X; Yu Y; Lu Z; Bast RC; Hua K; Feng W
Epigenetics; 2013 Dec; 8(12):1330-46. PubMed ID: 24135786
[TBL] [Abstract][Full Text] [Related]
31. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress.
Zhang Q; Yu S; Lam MMT; Poon TCW; Sun L; Jiao Y; Wong AST; Lee LTO
J Exp Clin Cancer Res; 2019 Mar; 38(1):116. PubMed ID: 30845964
[TBL] [Abstract][Full Text] [Related]
33. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W
Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.
Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G
Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
36. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics.
Zhang S; O'Regan R; Xu W
Cancer; 2020 Mar; 126(5):939-948. PubMed ID: 31869450
[TBL] [Abstract][Full Text] [Related]
37. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
Buechel M; Herzog TJ; Westin SN; Coleman RL; Monk BJ; Moore KN
Ann Oncol; 2019 May; 30(5):721-732. PubMed ID: 30887020
[TBL] [Abstract][Full Text] [Related]
38. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
RosanĂ² L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
39. RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.
Liu YB; Mei Y; Long J; Zhang Y; Hu DL; Zhou HH
J Exp Clin Cancer Res; 2018 Aug; 37(1):182. PubMed ID: 30075819
[TBL] [Abstract][Full Text] [Related]
40. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]